AMICUS THERAPEUTICS RAISES $55 MILLION SERIES C FINANCING
Amicus Therapeutics, a biopharmaceutical company
developing small-molecule, orally-active pharmacological chaperones for the
treatment of human genetic diseases, today announced the closing of a $55 million
Series C financing. The company intends to use the proceeds to advance its drug
pipeline based on the company's unique technology that has the potential to
transform the treatment of human genetic diseases. Amicus' lead compound Amigal(TM)
(migalastat hydrochloride) is in a Phase II clinical program for Fabry disease.